The practice of removing a well-fixed cementless
femoral component is associated with high morbidity. Ceramic bearing
couples are low wearing and their use minimises the risk of subsequent
further revision due to the production of wear debris. A total of
165 revision hip replacements were performed, in which a polyethylene-lined acetabular
component was revised to a new acetabular component with a ceramic
liner, while retaining the well-fixed femoral component. A titanium
sleeve was placed over the used femoral trunnion, to which a ceramic
head was added. There were 100 alumina and 65 Delta bearing couples
inserted. The mean Harris hip score improved significantly from 71.3 (9.0
to 100.0) pre-operatively to 91.0 (41.0 to 100.0) at a mean follow
up of 4.8 years (2.1 to 12.5) (p <
0.001). No patients reported
squeaking of the hip. There were two fractures of the ceramic head, both in alumina
bearings. No liners were seen to fracture. No fractures were observed
in components made of Delta ceramic. At 8.3 years post-operatively
the survival with any cause of failure as the endpoint was 96.6%
(95% confidence interval (CI) 85.7 to 99.3) for the acetabular component and
94.0% (95% CI 82.1 to 98.4) for the femoral component. The technique of revising the acetabular component in the presence
of a well-fixed femoral component with a ceramic head placed on
a titanium sleeve over the used trunnion is a useful adjunct in
revision hip practice. The use of Delta ceramic is recommended. Cite this article:
We performed a randomised, controlled trial involving 150 patients with a pre-operative level of haemoglobin of 13.0 g/dl or less, to compare the effect of either topical fibrin spray or intravenous tranexamic acid on blood loss after total knee replacement. A total of 50 patients in the topical fibrin spray group had 10 ml of the reconstituted product applied intra-operatively to the operation site. The 50 patients in the tranexamic acid group received 500 mg of tranexamic acid intravenously five minutes before deflation of the tourniquet and a repeat dose three hours later, and a control group of 50 patients received no pharmacological intervention. There was a significant reduction in the total calculated blood loss for those in the topical fibrin spray group (p = 0.016) and tranexamic acid group (p = 0.041) compared with the control group, with mean losses of 1190 ml (708 to 2067), 1225 ml (580 to 2027), and 1415 ml (801 to 2319), respectively. The reduction in blood loss in the topical fibrin spray group was not significantly different from that achieved in the tranexamic acid group (p = 0.72).
